Selection of first-line therapy for advanced follicular lymphoma

Journal of Clinical Oncology

Volumn 31, Issue 12, 2013, Pages 1496-1498

  Press, Oliver W ^a   Palanca Wessels, Maria Corinna ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; DRUG EFFICACY; EDITORIAL; FOLLICULAR LYMPHOMA; HUMAN; MAINTENANCE THERAPY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE;

EID: 84876568679     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.7315     Document Type: Editorial

References (16)

1. Solal-Cé ligny P, Lepage E, Brousse N, et al: Doxorubicin- containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d' Etude des Lymphomes Folliculaires 86 trial. J Clin Oncol 16:2332-2338, 1998 (Pubitemid 28309024)
2. Zelenetz AD, Abramson JS, Advani RH, et al: Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 9:484- 560, 2011
3. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008
4. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improve s the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
5. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An Ea st German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007 (Pubitemid 46972781)
6. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 112:4824-4831, 2008
7. Federico M, Luminari S, Dondi A, et al: R-CVP versus R-CHOP versus R-FM for the initial treatment of pat ients with advanced-stage follicular lymphoma: Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 31:1506- 1513, 2013
8. Kluin-Nelemans HC, Hoster E, Hermine O, et al: Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367:520-531, 2012
9. Sacchi S, Marcheselli L, Bari A, et al: Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study. Haematologica 93:398-404, 2008 (Pubitemid 351398641)
10. Press OW, Unger JM, Braziel RM, et al: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin' s lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24:4143-4149, 2006 (Pubitemid 46622291)
11. Press OW, Unger JM, Rimsza LM, et al: Phase III randomized Intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodinetositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 31:314 -320, 2013
12. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3 , randomised controlled trial. Lancet 377:42-51, 2011
13. Morschhauser F, Seymour JF, Feugier P, et al: Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study. Ann Oncol 22:89, 2011 (suppl 4; abstr 022)
14. Flinn IW, Van der Jagt RH, Kahl BS, et al: An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincr istine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin' s lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright Study. 54th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 8-11, 2012 (abstr 902)
15. Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An ope n-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet [epub ahead of print on February 19, 2013
16. Morschhauser F, Radford J, Van Hoof A, et al: Phase III trial of consolidation the rapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008